---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-078736"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:46:26.468711+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kyverna appoints Warner Biddle CEO, Christi Shaw to board; Maag resigns

## Summary
- Warner Biddle appointed CEO and Class III director, effective Sept 16; previously SVP Global Head of Commercial at Kite Pharma.
- Biddle receives 2,579,259-share option (4-year vest, 1-yr cliff), $625K salary, $650K sign-on bonus, and up to $150K relocation.
- Peter Maag, Ph.D. resigned as CEO and director Sept 13; will provide contractor services for up to 6 mo at $45,833/mo plus $550K severance.
- Christi Shaw appointed Class II director; granted option for $350K in shares vesting over 36 months; succeeded Brian Kotzin, who resigned.
- Company adopted 2024 Inducement Equity Incentive Plan reserving 4M shares for new-hire equity grants, used for Biddle's option.

## SEC filing metadata
- accession: 0001213900-24-078736
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000121390024078736/0001213900-24-078736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000121390024078736/ea0214607-8k_kyverna.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-078736
- JSON: https://secwatch.observer/filing/0001213900-24-078736.json
- Plain text: https://secwatch.observer/filing/0001213900-24-078736.txt

## Key facts
- Executive change
  Warner Biddle was appointed as Chief Executive Officer and Class III director at Kyverna Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer and Class III director
  source text: appointed Warner Biddle as the Company’s Chief Executive Officer and as a Class III director of the Company, in each case effective September 16, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1994702/000121390024078736/0001213900-24-078736-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.